Emerging Topical and Systemic JAK Inhibitors in Dermatology

December 2019 in “ Frontiers in Immunology ”

Farzan Solimani, Katharina Meier, Kamran Ghoreschi

Janus kinase inhibitors JAK inhibitors alopecia areata atopic dermatitis psoriasis cytokines systemic administration topical administration JAKi

Studysummary This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The document reviewed the emerging role of Janus kinase inhibitors (JAKi) in dermatology, focusing on their potential for treating conditions like alopecia areata (AA), atopic dermatitis (AD), psoriasis vulgaris (PSO), and vitiligo. JAKi, such as tofacitinib and baricitinib, showed promise in modulating cytokine signaling pathways, leading to hair regrowth in AA and symptom improvement in AD and PSO. However, effects were often temporary and reversed upon discontinuation. In vitiligo, JAKi aided repigmentation, especially with phototherapy. Challenges included developing selective JAKi to minimize toxicity risks, such as anemia and elevated cholesterol. While newer JAKi showed improved selectivity, concerns about infections and long-term risks persisted. Economically, JAKi were favorable, but further research was needed to confirm their efficacy and safety compared to traditional treatments.

View this study on frontiersin.org →

Discuss this study in the Community →

Research cited in this study

21 / 21 results

research Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases

88 citations , August 2019 in “Frontiers in immunology”

This review discusses the role of tyrosine kinase signaling pathways in autoimmune and inflammatory skin diseases and reports no new clinical results, highlighting ongoing research into small-molecule tyrosine kinase inhibitors as potential treatments.

research Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata

32 citations , April 2019 in “JAAD case reports”

This study discusses the immune dysregulation observed in individuals with Down syndrome, highlighting their increased risk for autoimmune skin conditions, but does not yet clarify the molecular mechanisms behind this profile.

research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis

130 citations , February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.

research JAK Inhibitors and Alopecia Areata

56 citations , January 2019 in “Lancet”

This review discusses the emerging use of JAK inhibitors in alopecia areata treatment and reports no new clinical results; it highlights hair regrowth despite symptom recurrence after stopping therapy.

research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

66 citations , December 2018 in “Dermatology”

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata

11 citations , December 2018 in “Journal of the European Academy of Dermatology and Venereology”

This article is a Letter to the Editor discussing rebound effects associated with JAK inhibitor use in treating alopecia areata and reports no new clinical results.

research Topical Tofacitinib Solution for the Treatment of Alopecia Areata Affecting Eyelashes

24 citations , October 2018 in “JAAD Case Reports”

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series

79 citations , September 2018 in “Dermatologic therapy”

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

research Simultaneous Improvement of Alopecia Universalis and Atopic Dermatitis in a Patient Treated with a JAK Inhibitor

16 citations , June 2018 in “JAAD case reports”

This article reviews the differences in inflammatory processes between alopecia universalis and atopic dermatitis, focusing on type 1 and type 2 immune responses, but it reports no new results.

research Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology

63 citations , April 2018 in “Journal of the American Academy of Dermatology”

This review discusses the efficacy and safety of topical JAK inhibitors for inflammatory skin conditions, reporting modest benefits in psoriasis and atopic dermatitis but mixed results for vitiligo and inconclusive data for alopecia areata.

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations , February 2018 in “Journal of Investigative Dermatology”

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata

83 citations , June 2017 in “Journal of the American Academy of Dermatology”

This study observed that most pediatric patients with alopecia areata experienced some hair regrowth after treatment with topical JAK inhibitors, and the formulations were generally well-tolerated with mild lab abnormalities in some cases.

research Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents

139 citations , November 2016 in “Journal of the American Academy of Dermatology”

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

research Drug Delivery with Topically Applied Nanoparticles: Science Fiction or Reality?

39 citations , January 2013 in “Skin pharmacology and physiology”

This article reviews the potential of nanoparticles for drug delivery through the skin barrier and highlights the need for further research on solid nanoparticles, as they lack commercial development for this purpose.

research Alopecia Areata: An Autoimmune Disease Causing Hair Loss

421 citations , April 2012 in “The New England Journal of Medicine”

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

research Graft-Versus-Host Disease: Comprehensive Overview by the American Academy of Dermatology

58 citations , April 2012 in “Journal of the American Academy of Dermatology”

Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.

research Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity

717 citations , June 2010 in “Nature”

This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.